| Rituxan (rituximab) / Roche |
NCT02693210: A Study to Evaluate the Efficacy and Safety of Mabthera Alone and in Combination With Either Cyclophosphamide or Methotrexate in Patients With Rheumatoid Arthritis |
|
|
| Completed | 2 | 161 | Canada, Europe, RoW | Cyclophosphamide, Methotrexate, Placebo Cyclophosphamide, Placebo Methotrexate, Placebo Rituximab, Rituximab | Hoffmann-La Roche | Rheumatoid Arthritis | 08/02 | 08/04 | | |
NCT00074438: Study to Assess the Efficacy and Safety of Rituximab in Patients With Rheumatoid Arthritis |
|
|
| Completed | 2 | 465 | US | methotrexate, rituximab, corticosteroids, placebo | Genentech, Inc., Roche Pharma AG | Rheumatoid Arthritis | 09/04 | 07/11 | | |
SIERRA, NCT00282308: A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate |
|
|
| Completed | 2 | 103 | US | Rituximab, Rituxan, MabThera, Methotrexate, Methylprednisone, C. albicans, Tetanus toxoid adsorbed booster vaccine, 23-valent pneumococcal polysaccharide vaccine, Keyhole limpet hemocyanin | Genentech, Inc. | Rheumatoid Arthritis | 01/08 | 05/12 | | |
NCT00446251: Effects of Rituximab and Mycophenolate Mofetil (MMF) on Highly Sensitized Patients Awaiting Renal Transplant |
|
|
| Completed | 2 | 14 | US | Rituximab, Rituxan, Rituximab, Mycophenolate mofetil (MMF), mycophenolate mofetil, MMF, Cellcept | University of Washington, Genentech, Inc. | Kidney Failure, Chronic, Diabetic Nephropathies, Glomerulonephritis, IGA, Hypertension, Renal | 04/08 | 12/08 | | |
RUMBA, NCT00243412: A Study of the Safety and Efficacy of Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis Receiving Methotrexate |
|
|
| Completed | 2 | 42 | US | folate, methotrexate, methylprednisolone, Placebo, Rituximab | Genentech, Inc. | Rheumatoid Arthritis | 02/09 | 02/09 | | |
NCT00298272: Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis |
|
|
| Terminated | 2 | 54 | US | IDEC-C2B8 (rituximab), Rituxan, Placebo, Methotrexate, Etanercept, Enbrel, Adalimumab, Humira, Methylprednisolone, Folate | Biogen, Hoffmann-La Roche, Genentech, Inc. | Rheumatoid Arthritis | 04/09 | 07/11 | | |
NCT00422942 / 2005-003632-22: A Pharmacokinetic and Pharmacodynamic Study of MabThera (Rituximab) Plus Methotrexate in Patients With Rheumatoid Arthritis (RA) |
|
|
| Terminated | 2 | 3 | Europe | rituximab [MabThera/Rituxan], Methotrexate | Hoffmann-La Roche | Rheumatoid Arthritis | 06/10 | 06/10 | | |
NCT00372892: Pilot Study of Rituximab for the Treatment of Acute Immune Thrombocytopenic Purpura (ITP) |
|
|
| Completed | 2 | 60 | Canada | Rituximab, Rituxan, Mabthera, Placebo | Hamilton Health Sciences Corporation, Hoffmann-La Roche | Purpura, Thrombocytopenic, Idiopathic | 12/10 | 06/11 | | |
NCT00475423: A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura. |
|
|
| Completed | 2 | 122 | RoW | rituximab [MabThera/Rituxan] | Hoffmann-La Roche | Idiopathic Thrombocytopenic Purpura | 08/11 | 08/11 | | |
| Completed | 2 | 30 | Europe | Rituximab | Assistance Publique - Hôpitaux de Paris, Institut National de la Santé Et de la Recherche Médicale, France, Roche Pharma AG | Myositis, Myasthenia Gravis | 12/11 | 12/11 | | |
|
NCT02093026: Extension Study to Assess the Efficacy and Safety of Repeat Treatment With Rituximab (MabThera) in Participants With Active Rheumatoid Arthritis (RA) |
|
|
| Completed | 2 | 465 | US, Canada, Europe, RoW | Rituximab, MabThera, Rituxan, Methotrexate, Methylprednisolone, Folic Acid | Hoffmann-La Roche, Genentech, Inc. | Rheumatoid Arthritis | 12/12 | 12/12 | | |
RITAPS, NCT00537290: A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome |
|
|
| Completed | 2 | 19 | US | Rituximab, Rituxan | Hospital for Special Surgery, New York, Genentech, Inc. | Antiphospholipid Syndrome | 01/13 | 01/13 | | |
NCT00845832 / 2008-005525-11: A Study of Combination Treatment With MabThera (Rituximab) and RoActemra (Tocilizumab) Versus RoActemra in Patients With Rheumatoid Arthritis With an Incomplete Response to Methotrexate |
|
|
| Terminated | 2 | 24 | Europe | Placebo, rituximab [MabThera/Rituxan], tocilizumab [RoActemra/Actemra] | Hoffmann-La Roche | Rheumatoid Arthritis | 03/13 | 03/13 | | |
NCT02222155: Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis |
|
|
| Completed | 2 | 42 | Canada, US | CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids, CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids, Placebo, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids | ChemoCentryx | ANCA-associated Vasculitis | 04/16 | 07/16 | | |
NCT01713738: Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP) |
|
|
| Completed | 1/2 | 36 | US | rituximab | Neufeld, Ellis J, MD, PhD, Genentech, Inc., Biogen, Glaser Pediatric Research Network, Terrana ITP Research Fund | Idiopathic Thrombocytopenic Purpura (ITP), Immune Thrombocytopenic Purpura (ITP) | 12/05 | 12/05 | | |
NCT00584935: Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid |
|
|
| Completed | 1/2 | 3 | US | Rituximab | University of Alabama at Birmingham, Genentech, Inc., Biogen | Ocular Cicatricial Pemphigoid | 01/10 | 05/10 | | |
| Completed | 1/2 | 312 | US, Europe, RoW | GP2013, MabThera, EU-Rituximab, Rituxan, US-Rituximab | Sandoz, Novartis Pharmaceuticals | Rheumatoid Arthritis | 01/16 | 11/16 | | |
|
|
NCT02495129: Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sjögren's Syndrome |
|
|
| Withdrawn | 1/2 | 0 | NA | VAY736 lower dose, VAY736 higher dose | Novartis Pharmaceuticals | Primary Sjögren's Syndrome | 09/17 | 09/17 | | |
